Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Empower Clinics and Cannvas MedTech launch program to educate patients on alternative CBD therapies

Proactive Investors Thursday, 18 April 2019
Empower Clinics Inc (CSE:CBDT) (OTCMKTS:EPWCF) is partnering with a leading digital cannabis analytics company to place educational kiosks in each of its clinics to provide information, data and analysis of physician-recommended alternative CBD therapies. Together with its partner, Cannvas MedTech Inc (CSE:MTEC) (OTCMTKS:CANVF), Empower is initiating a pilot program to launch a comprehensive education, data collection and analysis program that sees Cannvas kiosks installed in Empower’s medical clinics. READ: Empower Clinics plans to change name to CBD Therapeutics The new partnership comes as Empower repositions its overall strategy to become a vertically integrated health and wellness company that connects to its 120,000 patients using a data-driven focus to improve patients' lives with products, technology and health systems, CEO Steven McAuley said in a statement. “The addition of the Cannvas educational kiosks, a user friendly and highly interactive education platform, is a tremendous step forward to making our brand one of the go-to sources for content for both patients and the medical community nationwide,” he said. Cannvas’ CEO Shawn Moniz said that the partnership represents an opportunity to bring unbiased cannabis education to a large population of patients looking for therapies to alleviate a number of ailments, while also learning more about what behaviours may drive the decision to look at cannabis as an alternative or complementary treatment. Cannvas will be a key data and analytics partner for Empower by providing insights on customer behaviours and industry trends and integrating existing data partnerships. Empower also plans to begin further pilot initiatives with Cannvas to provide content and educational links to and directly from the new Empower website and through its tele-medicine portal. Shares of Empower closed Wednesday at C$0.17 in Canada and US$0.14 in the US, while Cannvas shares were at C$0.26 in Canada and US$0.19 in the US. Contact Angela at [email protected] Follow her on Twitter @AHarmantas

Recent related videos from verified sources

U.S. Doctors Prescribe Opioid Painkillers To 75% Of Patients Following Low-Risk Surgery [Video]U.S. Doctors Prescribe Opioid Painkillers To 75% Of Patients Following Low-Risk Surgery

New research shows that U.S. doctors are more likely to prescribe opioids to patients after surgery than those in other countries. Studies show that over 75% of patients in the U.S.are prescribed..

Credit: Wochit     Duration: 00:35Published

Recent related news from verified sources

Kazia Therapeutics' cancer drug trials lift valuation to $137 million or $2.20 a share, according to Edison

Kazia Therapeutics Ltd (ASX:KZA) has had its valuation updated to A$137 million or A$2.20 a share by Edison Investment Research Limited, which maintains its base...
Proactive Investors

Paradigm Biopharmaceuticals gets FDA clearance for investigational new drug application

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has confirmed that its first Investigational New Drug (IND) application (filed in August 2019) has been cleared by the...
Proactive Investors

You Might Like

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.